molecules

an Open Access Journal by MDPI

IMPACT FACTOR 4.6

Indexed in: PubMed

CITESCORE 6.7

Next Generation Histone Deacetylase (HDAC) Inhibitors

Guest Editors:

Prof. Dr. Thomas Kurz
Heinrich-Heine-Universität Düsseldorf, Institute for Pharmaceutical and Medicinal Chemistry, Universitätsstraße 1, 40225 Düsseldorf, Germany

Prof. Dr. Finn K. Hansen
Institute of Pharmacy, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany

Deadline for manuscript submissions:
closed (31 January 2019)

Message from the Guest Editors

Dear Colleagues,

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for the treatment of cancer. Thus far, four histone deacetylase inhibitors (HDACi) have been approved by the FDA to combat certain types of lymphoma or multiple myeloma. Furthermore, there is growing evidence that HDACi have therapeutic potential in several diseases beyond cancer, such as inflammation, HIV, and parasitic and neurodegenerative diseases. First-generation inhibitors are non-selective HDACi that target multiple isoforms which might lead to serious side effect. In the field of cancer, it is currently under debate whether class- or isoform-selective HDACi can provide improved risk-benefit profiles compared to first-generation pan-inhibitors. In the field of non-oncology diseases, it is evident that the use of pan-HDACi is limited due to their side effects.

The aim of this Special Issue is to highlight recent efforts in the design, synthesis, and pharmacological evaluation of next-generation histone deacetylase inhibitors. We welcome original articles and short communications as well as review articles.

Prof. Dr. Thomas Kurz
Prof. Dr. Finn K. Hansen
Guest Editors

molecules

IMPACT FACTOR 4.6 | Indexed in: PubMed | CITESCORE 6.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
𝕏@Molecules_MDPI